Ticker >

Brooks Laboratories share price

Brooks Laboratories Ltd.

NSE: BROOKS BSE: 533543 SECTOR: Pharmaceuticals & Drugs  15k   14   0

108.95
+2.10 (1.97%)
NSE: 26 Apr 04:02 PM

Price Summary

Today's High

₹ 108.95

Today's Low

₹ 108.95

52 Week High

₹ 185.7

52 Week Low

₹ 56.95

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

285.96 Cr.

Enterprise Value

290.55 Cr.

No. of Shares

2.62 Cr.

P/E

568.63

P/B

4.13

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  26.39

CASH

1.08 Cr.

DEBT

5.66 Cr.

Promoter Holding

63.59 %

EPS (TTM)

₹  0.19

Sales Growth

-27.84%

ROE

-13.45 %

ROCE

-11.22%

Profit Growth

-1329.91 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-27.84%
3 Year-7.29%
5 Year-0.06%

Profit Growth

1 Year-1329.91%
3 Year18.5%
5 Year7.07%

ROE%

1 Year-13.45%
3 Year-10.53%
5 Year-14.01%

ROCE %

1 Year-11.22%
3 Year-4.86%
5 Year-6.19%

Debt/Equity

0.0997

Price to Cash Flow

508.64

Interest Cover Ratio

-9.68370940393896

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 63.59 0
Dec 2023 63.59 0
Sep 2023 63.59 0
Jun 2023 66.41 0
Mar 2023 66.41 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of -38.5983546163263 days.
  • The company has a high promoter holding of 63.59%.

 Limitations

  • The company has shown a poor revenue growth of -7.28641629966465% for the Past 3 years.
  • Company has a poor ROE of -10.5303621949137% over the past 3 years.
  • Company has a poor ROCE of -4.86214785148968% over the past 3 years
  • Company has contingent liabilities of 19.7635 Cr.
  • The company has a low EBITDA margin of -5.52730790424941% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 95.1131.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 12 12.61 15.7 24.32 21.75
Total Expenditure 13.48 12.73 15.68 22.6 20.65
Operating Profit -1.47 -0.12 0.03 1.72 1.1
Other Income 0.06 0.02 0.06 0.09 0.16
Interest 0.24 0.18 0.17 0.19 0.21
Depreciation 0.43 0.44 0.44 0.44 0.44
Exceptional Items 0 0 0 0 0
Profit Before Tax -2.08 -0.72 -0.53 1.18 0.6
Tax 0 0 0 0 0.03
Profit After Tax -2.08 -0.72 -0.53 1.18 0.58
Adjusted EPS (Rs) -0.83 -0.29 -0.21 0.45 0.22

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 55.03 69.69 77.27 76.97 55.54
Total Expenditure 63.39 73.61 76.33 75.09 61.35
Operating Profit -8.36 -3.92 0.95 1.87 -5.81
Other Income 2.88 0.41 0.96 0.95 0.11
Interest 2.96 3.35 3.25 0.67 0.77
Depreciation 6.5 6.65 7.09 1.49 1.72
Exceptional Items 0 0 0 0 0
Profit Before Tax -14.95 -13.51 -8.44 0.67 -8.19
Tax -0.14 10.86 7.15 0 0
Net Profit -14.81 -24.38 -15.59 0.67 -8.19
Adjusted EPS (Rs.) -7.55 -9.77 -6.25 0.27 -3.28

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 16.19 24.7 24.7 24.7 24.7
Total Reserves 88.96 73.71 39.51 40.3 32.08
Borrowings 13.86 11.4 1.34 0 0
Other N/C liabilities -9.44 2.25 1.76 2.99 2.62
Current liabilities 47.39 45.8 25.69 35.46 33.02
Total Liabilities 156.97 157.86 93 103.45 92.42
Assets
Net Block 117.25 113.02 14.96 15.14 15.01
Capital WIP 0 0 0 1.12 0
Intangible WIP 0.29 0.11 0.02 0 0
Investments 0.47 0.02 46.81 46.84 46.85
Loans & Advances 7.04 6.68 3.04 3.1 2.79
Other N/C Assets 0.18 0.11 2.83 0.22 0.17
Current Assets 31.74 37.92 25.34 37.04 27.61
Total Assets 156.97 157.86 93 103.45 92.42
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations -14.95 -13.51 -8.44 0.67 -8.19
Adjustment 9.24 11.76 10.23 2.43 2.79
Changes in Assets & Liabilities 1.22 -7.62 1.51 0.29 6.15
Tax Paid -0.56 -0.01 -4.2 -0.26 -0.19
Operating Cash Flow -5.05 -9.39 -0.9 3.12 0.56
Investing Cash Flow 1.12 -2.33 -0.74 1.12 -0.4
Financing Cash Flow 5.78 9.61 1.31 -4.23 -0.22
Net Cash Flow 1.85 -2.1 -0.33 0.02 -0.06

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 66.41 66.41 63.59 63.59 63.59
aryan majahan - - - - 4.60
atul ranchal 25.35 25.35 23.86 23.86 23.86
davinder kumari 0.15 0.15 0.15 0.15 0.15
erwin mahajan 4.60 4.60 4.60 4.60 4.60
rajesh mahajan 20.70 20.70 19.48 19.48 19.48
rajni ranchal 3.49 3.49 3.28 3.28 3.28
saras gupta 3.26 3.26 3.07 3.07 3.07
savvy ranchal 2.82 2.82 3.00 3.00 3.00
selina ranchal 1.45 1.45 1.55 1.55 1.55
aryan mahajan 4.60 4.60 4.60 4.60 -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 33.59 33.59 36.41 36.41 36.41
brj resources private - - 1.60 - 1.60
llp 0.36 0.36 0.34 0.40 0.46
quant mutual fund-busines... - - - - 3.86
brj resources private lim... - - - 1.60 -
quant mutual fund - quant... - - - 3.86 -
quant mutual fund - quant... - - 2.46 - -
tipsons financial service... - 1.10 - - -
tipson financial services... 1.03 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Brooks Laboratories informs about compliance certificate4 Apr 2024, 5:40PM Brooks Laboratories - Quaterly Results31 Jan 2024, 6:05PM Brooks Laboratories - Quaterly Results31 Jan 2024, 6:05PM Brooks Laboratories - Quaterly Results31 Jan 2024, 6:05PM Brooks Laboratories informs about board meeting24 Jan 2024, 5:09PM Brooks Laboratories informs about press release1 Sep 2023, 3:50PM Brooks Laboratories - Quaterly Results10 Aug 2023, 4:28PM Brooks Laboratories - Quaterly Results10 Aug 2023, 4:28PM Brooks Laboratories informs about resignation of director8 Jul 2023, 10:47AM Brooks Laboratories informs about disclosure3 Jun 2023, 2:55PM Brooks Laboratories informs about clarification 3 May 2023, 4:50PM Brooks Laboratories informs about compliance certificate11 Apr 2023, 4:30PM Brooks Laboratories informs about postal ballot report4 Mar 2023, 3:36PM Brooks Laboratories informs about notice of postal ballot 25 Nov 2022, 4:29PM Brooks Laboratories - Quaterly Results14 Nov 2022, 6:39PM Brooks Laboratorie informs about updates22 Aug 2022, 2:53PM Brooks Laboratories’ arm gets USFDA’s nod for Meropenem Injection 22 Aug 2022, 9:20AM Brooks Laboratories informs about outcome of board meeting10 Aug 2022, 4:49PM Brooks Laboratories - Quaterly Results10 Aug 2022, 3:05PM Brooks Laboratories’ arm gets marketing authorization in UK by MHRA23 May 2022, 1:00PM Brooks Laboratories’ arm enters into distribution and supply agreement with Armas Pharmaceuticals10 May 2022, 2:39PM Brooks Laboratories informs about trading window closure23 Mar 2022, 4:47PM Brooks Laboratories’ arm gets marketing authorization for Meropenem in Germany29 Nov 2021, 3:30PM Brooks Laboratories informs about trading window closure29 Sep 2021, 3:24PM Brooks Laboratories acquires 44.33% stake in SteriBrooks Penems 18 Sep 2020, 9:50AM Brooks Laboratories partners with SteriScience17 Sep 2020, 4:52PM Brooks Laboratories informs about outcome of board meeting13 Apr 2020, 11:00AM

Brooks Laboratories Stock Price Analysis and Quick Research Report. Is Brooks Laboratories an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Brooks Laboratories and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Brooks Laboratories cash from the operating activity was Rs 0.5622 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Brooks Laboratories has a Debt to Equity ratio of 0.0997 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Brooks Laboratories , the EPS growth was -1329.88764044944 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Brooks Laboratories has OPM of -10.4690482192373 % which is a bad sign for profitability.
     
  • ROE: Brooks Laboratories have a poor ROE of -13.4522343203429 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Brooks Laboratories is Rs 108.95. One can use valuation calculators of ticker to know if Brooks Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Brooks Laboratories
X